Board Meeting3 Aug 2026, 04:12 pm
GSK Pharma Board Approves Q1 FY27 Unaudited Results; Management Changes
AI Summary
GlaxoSmithKline Pharmaceuticals Ltd announced the outcome of its Board Meeting held on August 3, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026. Key management changes include the stepping down of Non-Executive Director Mr. Subesh Williams and the appointment of Ms. Karine J F Natland as a Non-Executive Director. Additionally, Mr. Bhushan Akshikar has been re-appointed as Managing Director for a term of two years effective December 1, 2026. The company reported revenue from operations of ₹92,442 Lakhs and other income of ₹6,163 Lakhs for the quarter.
Key Highlights
- Board approved Q1 FY27 unaudited standalone and consolidated financial results.
- Mr. Subesh Williams stepped down as Non-Executive Director.
- Ms. Karine J F Natland appointed as Non-Executive Director.
- Mr. Bhushan Akshikar re-appointed as Managing Director for two years.
- Q1 FY27 revenue from operations stood at ₹92,442 Lakhs.
Price Impact
More from GLAXO